There are a number complement inhibitors are in phase 1-3 clinical trials for the treatment of AMD (Table 2), including one inhibitor (POT-4) targeting C3, four (LFG316, Eculizumab, Zimura, and ARC1905) targeting C5, and another one targeting factor D (Lampalizumab formerly FCFD4514S). The gene discussed is C3; the disease is age-related macular degeneration.